 Donna Curtis
Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza A Virus, H1N1 Subtype | 6 | 2016 | 157 | 0.860 |
Why?
| | Influenza Vaccines | 3 | 2016 | 529 | 0.720 |
Why?
| | Influenza, Human | 7 | 2016 | 617 | 0.640 |
Why?
| | Immunocompromised Host | 2 | 2019 | 201 | 0.560 |
Why?
| | Orthomyxoviridae | 2 | 2015 | 40 | 0.470 |
Why?
| | West Nile Fever | 1 | 2016 | 57 | 0.460 |
Why?
| | Virus Shedding | 1 | 2015 | 48 | 0.450 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 80 | 0.430 |
Why?
| | Antibodies, Viral | 2 | 2016 | 672 | 0.420 |
Why?
| | Vaccines, Attenuated | 3 | 2020 | 129 | 0.380 |
Why?
| | Vaccination | 5 | 2020 | 1423 | 0.370 |
Why?
| | HIV Infections | 2 | 2015 | 3154 | 0.300 |
Why?
| | Kidney Transplantation | 1 | 2016 | 704 | 0.300 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2021 | 676 | 0.280 |
Why?
| | Hemagglutination Inhibition Tests | 3 | 2016 | 38 | 0.260 |
Why?
| | Postoperative Complications | 2 | 2016 | 2920 | 0.250 |
Why?
| | Organ Transplantation | 2 | 2019 | 248 | 0.240 |
Why?
| | Cross Infection | 2 | 2019 | 262 | 0.230 |
Why?
| | Child | 19 | 2023 | 22657 | 0.220 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2017 | 249 | 0.200 |
Why?
| | Respiratory Tract Infections | 2 | 2022 | 398 | 0.200 |
Why?
| | Liver Transplantation | 2 | 2020 | 823 | 0.190 |
Why?
| | Staphylococcal Infections | 2 | 2017 | 390 | 0.190 |
Why?
| | Enterovirus Infections | 2 | 2016 | 173 | 0.180 |
Why?
| | Intensive Care Units | 3 | 2017 | 916 | 0.180 |
Why?
| | Child, Preschool | 9 | 2019 | 11799 | 0.180 |
Why?
| | Hospitalization | 4 | 2019 | 2434 | 0.170 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 35 | 0.160 |
Why?
| | Laboratories | 1 | 2021 | 109 | 0.160 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 130 | 0.150 |
Why?
| | Carrier State | 2 | 2017 | 79 | 0.150 |
Why?
| | Pediatrics | 2 | 2019 | 1115 | 0.150 |
Why?
| | Opportunistic Infections | 1 | 2019 | 45 | 0.150 |
Why?
| | Advisory Committees | 1 | 2020 | 230 | 0.140 |
Why?
| | Infection Control | 2 | 2017 | 172 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2021 | 163 | 0.140 |
Why?
| | Transplant Recipients | 1 | 2020 | 180 | 0.140 |
Why?
| | Postoperative Care | 1 | 2020 | 288 | 0.140 |
Why?
| | Mucositis | 1 | 2018 | 20 | 0.140 |
Why?
| | Hospital Costs | 1 | 2019 | 124 | 0.140 |
Why?
| | Adolescent | 9 | 2022 | 22453 | 0.130 |
Why?
| | Respiration, Artificial | 1 | 2022 | 708 | 0.130 |
Why?
| | Triazoles | 1 | 2018 | 184 | 0.120 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2016 | 22 | 0.120 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 70 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2017 | 220 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 887 | 0.120 |
Why?
| | Graft vs Host Disease | 1 | 2018 | 264 | 0.120 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1054 | 0.120 |
Why?
| | Cytomegalovirus | 1 | 2016 | 168 | 0.110 |
Why?
| | Nasopharynx | 1 | 2015 | 73 | 0.110 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 87 | 0.110 |
Why?
| | Humans | 25 | 2023 | 144957 | 0.110 |
Why?
| | DNA, Viral | 1 | 2016 | 358 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 847 | 0.110 |
Why?
| | Colorado | 7 | 2021 | 4564 | 0.110 |
Why?
| | Immunoglobulin A | 1 | 2015 | 214 | 0.100 |
Why?
| | Vaccines | 1 | 2019 | 389 | 0.100 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2014 | 64 | 0.100 |
Why?
| | Male | 14 | 2019 | 72406 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 851 | 0.100 |
Why?
| | Cerebrovascular Disorders | 1 | 2014 | 103 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 257 | 0.090 |
Why?
| | Internship and Residency | 1 | 2023 | 1257 | 0.090 |
Why?
| | Retrospective Studies | 11 | 2022 | 17101 | 0.090 |
Why?
| | Immunologic Memory | 1 | 2015 | 366 | 0.090 |
Why?
| | Picornaviridae Infections | 1 | 2012 | 50 | 0.090 |
Why?
| | Mass Screening | 2 | 2017 | 1348 | 0.090 |
Why?
| | Herpesvirus 3, Human | 1 | 2014 | 336 | 0.080 |
Why?
| | Herpes Zoster | 1 | 2014 | 315 | 0.080 |
Why?
| | Young Adult | 2 | 2015 | 14126 | 0.070 |
Why?
| | Pandemics | 2 | 2020 | 1695 | 0.070 |
Why?
| | Female | 11 | 2019 | 78376 | 0.070 |
Why?
| | Nervous System Diseases | 1 | 2010 | 284 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4293 | 0.060 |
Why?
| | Cytokines | 1 | 2015 | 2065 | 0.060 |
Why?
| | Adult | 5 | 2021 | 40506 | 0.060 |
Why?
| | Papillomavirus Vaccines | 1 | 2010 | 297 | 0.060 |
Why?
| | Cost-Benefit Analysis | 2 | 2019 | 636 | 0.060 |
Why?
| | Infectious Disease Medicine | 1 | 2023 | 12 | 0.050 |
Why?
| | Accreditation | 1 | 2023 | 101 | 0.050 |
Why?
| | Parents | 1 | 2010 | 1403 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 1416 | 0.040 |
Why?
| | Microbiology | 1 | 2021 | 24 | 0.040 |
Why?
| | Incidence | 2 | 2019 | 2883 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 91 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2021 | 151 | 0.040 |
Why?
| | Critical Pathways | 1 | 2020 | 108 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5417 | 0.040 |
Why?
| | Information Dissemination | 1 | 2020 | 223 | 0.030 |
Why?
| | United States | 3 | 2021 | 15988 | 0.030 |
Why?
| | Age Factors | 2 | 2019 | 3335 | 0.030 |
Why?
| | Interprofessional Relations | 1 | 2020 | 281 | 0.030 |
Why?
| | Morbidity | 1 | 2019 | 323 | 0.030 |
Why?
| | Needs Assessment | 1 | 2020 | 404 | 0.030 |
Why?
| | Models, Econometric | 1 | 2017 | 34 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 170 | 0.030 |
Why?
| | Allografts | 1 | 2018 | 150 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2017 | 121 | 0.030 |
Why?
| | Markov Chains | 1 | 2017 | 129 | 0.030 |
Why?
| | Patient Isolation | 1 | 2017 | 20 | 0.030 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 38 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 68 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 69 | 0.030 |
Why?
| | Program Evaluation | 1 | 2020 | 949 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 216 | 0.030 |
Why?
| | North America | 1 | 2016 | 310 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 415 | 0.030 |
Why?
| | Clinical Competence | 1 | 2023 | 1244 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2852 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 162 | 0.030 |
Why?
| | Viral Load | 1 | 2016 | 526 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 285 | 0.030 |
Why?
| | Cost of Illness | 1 | 2016 | 321 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2092 | 0.030 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 341 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2016 | 422 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 409 | 0.020 |
Why?
| | Rhinovirus | 1 | 2012 | 57 | 0.020 |
Why?
| | Enterovirus | 1 | 2012 | 82 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2022 | 1915 | 0.020 |
Why?
| | Quality Improvement | 1 | 2020 | 1291 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2119 | 0.020 |
Why?
| | Risk Factors | 2 | 2019 | 10792 | 0.020 |
Why?
| | Inpatients | 1 | 2015 | 546 | 0.020 |
Why?
| | Los Angeles | 1 | 2010 | 76 | 0.020 |
Why?
| | Parental Consent | 1 | 2010 | 25 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 892 | 0.020 |
Why?
| | Cohort Studies | 2 | 2010 | 5965 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3676 | 0.020 |
Why?
| | Infant | 2 | 2016 | 10039 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2925 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 6053 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 556 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2010 | 269 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2010 | 345 | 0.010 |
Why?
| | Prevalence | 1 | 2012 | 2836 | 0.010 |
Why?
| | Oxygen | 1 | 2010 | 995 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5872 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2016 | 6434 | 0.010 |
Why?
| | Antiviral Agents | 1 | 2010 | 768 | 0.010 |
Why?
| | Critical Care | 1 | 2010 | 697 | 0.010 |
Why?
| | Time Factors | 1 | 2015 | 7183 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 886 | 0.010 |
Why?
| | Mutation | 1 | 2014 | 4099 | 0.010 |
Why?
| | Brain | 1 | 2014 | 2941 | 0.010 |
Why?
| | Middle Aged | 2 | 2016 | 35928 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3869 | 0.010 |
Why?
| | Aged | 1 | 2010 | 25947 | 0.000 |
Why?
|
|
Curtis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|